Investor Relations
PURE Bioscience (NASDAQ: PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Corporate Fact Sheet
Third Quarter Results Conference Call: June 9, 2010
Lippert/Heilshorn Life Sciences & Medtech Virtual Conference July 20, 2010
PURE Bioscience Common Stock is listed on NASDAQ.
Stock Quote: PURE
Inquiries about stock accounts, dividends or change in name or address may be directed to PURE Bioscience's stock transfer agent:
Computershare Trust Company
350 Indiana Street, Suite 800
Golden,Co 80401
1.303.262.0600
Other investor inquires may be directed to:
Don Markley, Senior Vice President
Lippert/Heilshorn & Associates
(310) 691-7100 dmarkley@lhai.com